CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series
Language English Country United States Media print-electronic
Document type Case Reports, Journal Article
PubMed
29512859
DOI
10.1002/pbc.27003
Knihovny.cz E-resources
- Keywords
- ALK-positive ALCL, CNS, adolescence, childhood, progression, relapse,
- MeSH
- Anaplastic Lymphoma Kinase metabolism MeSH
- Lymphoma, Large-Cell, Anaplastic drug therapy pathology MeSH
- Molecular Targeted Therapy adverse effects MeSH
- Child MeSH
- Adult MeSH
- Humans MeSH
- Neoplasm Recurrence, Local drug therapy pathology MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Young Adult MeSH
- Central Nervous System Diseases chemically induced pathology MeSH
- Child, Preschool MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects MeSH
- Vinblastine adverse effects MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- ALK protein, human MeSH Browser
- Anaplastic Lymphoma Kinase MeSH
- Vinblastine MeSH
Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.
Children's Hospital Cottbus Cottbus Germany
Department of Internal Medicine Stauferklinikum Schwaebisch Gmuend Mutlangen Germany
Department of Pediatric Hematology and Oncology Justus Liebig University Giessen Giessen Germany
Department of Pediatric Hematology and Oncology University Hospital Ulm Ulm Germany
References provided by Crossref.org
